Does serum uric acid play a protective role against tissue damage in cardiovascular and metabolic diseases?
Article Sidebar
Main Article Content
Abstract
Previous clinical, observation and epidemiologic studies have demonstrated strong association between serum uric acid (SUA) and cardiovascular disease (hypertension, heart failure, and asymptomatic atherosclerosis), metabolic states (abdominal obesity, diabetes mellitus, metabolic syndrome, insulin resistance) and kidney disease. There is a large body of evidence regarding the role of SUA as predictor of CV events and CV mortality in general population and individuals with established CV disease and metabolic diseases. However, SUA may exhibit protective effects on endothelium and vasculature as well as attenuate endogenous repair system through mobbing and differentiation of cell precursors. Although SUA lowering drugs are widely used in patients with symptomatic hyperuricemia and gout beyond their etiologies, there is no agreement of SUA below target level 6.0 mg/dL in asymptomatic individuals with kidney injury and CV disease and data of ones are sufficiently limited. The short communication is depicted on the controversial role of SUA as primary cell toxicity agent and secondary cell protector against hypoxia, ischemia and apoptosis.
Article Details
Copyright (c) 2017 Berezin AE.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Scheepers LEJM, Boonen A, Dagnelie PC, Schram MT, van der Kallen CJH, et al. Uric acid and blood pressure: exploring the role of uric acid production in the Maastricht study. J Hypertens. 2017. Ref.: https://goo.gl/Gc8rfS
Lai CL, Xing JP, Liu XH, Qi J, Zhao JQ, et al. Relationships of Inflammatory Factors and Risk Factors with Different Target Organ Damage in Essential Hypertension Patients. Chin Med J (Engl). 2017; 130: 1296-1302. Ref.: https://goo.gl/WJrzXm
Magnoni M, Berteotti M, Ceriotti F, Mallia V, Vergani V, et al. Serum uric acid on admission predicts in-hospital mortality in patients with acute coronary syndrome. Int J Cardiol. 2017. Ref.: https://goo.gl/hEKwzE
Berezin AE. Prognostication in different heart failure phenotypes: the role of circulating biomarkers. J Circ Biomarkers. 2016, 5: 1. Ref.: https://goo.gl/X8HCBy
Berezin AE, Kremzer AA. Serum uric acid as a marker of coronary calcification in patients with asymptomatic coronary artery disease with preserved left ventricular pump function. Cardiol Res Pract. 2013. Ref.: https://goo.gl/iSkNLz
Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA, et al. The utility of biomarker risk prediction score in patients with chronic heart failure. Int J Clin Exp Med. 2015; 8: 18255-18264. Ref.: https://goo.gl/CAV9i4
Lai S, Mariotti A, Coppola B, Lai C, Aceto P, et al. Uricemia and homocysteinemia: nontraditional risk factors in the early stages of chronic kidney disease--preliminary data. Eur Rev Med Pharmacol Sci. 2014; 18: 1010-1017. Ref.: https://goo.gl/Uf6ARZ
Krajcoviechova A, Tremblay J, Wohlfahrt P, Bruthans J, Tahir MR, et al. The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid with Albuminuria in Adults without Full Metabolic Syndrome. Am J Hypertens. 2016; 29: 1335-1342. Ref.: https://goo.gl/ynFshq
Geraci G, Mulè G, Morreale M, Cusumano C, Castiglia A, et al. Association between uric acid and renal function in hypertensive patients: which role for systemic vascular involvement? J Am Soc Hypertens. 2016; 10: 559-569. Ref.: https://goo.gl/Cxckpu
Bharti S, Bharti B. Serum Uric Acid and Childhood Hypertension: Association to Causation to Prevention. Am J Hypertens. 2017. Ref.: https://goo.gl/X6KKCE
Berezin AE. Biological markers of cardiovascular diseases. Part 4. Diagnostic and prognostic value of biological markers at risk stratification among patients with heart failure. LAMBERT Academic Publishing GmbH, Moskow. 2015
Hsieh CH, Lin JD, Wu CZ, Hsu CH, Pei D, et al. Is lower uric acid level better? A combined cross-sectional and longitudinal study in the elderly. Endocrine. 2014; 47: 806-815. Ref.: https://goo.gl/825TFN
Wijnands JM, Houben AJ, Muris DM, Boonen A, Schram MT, et al. Uric acid and skin microvascular function: the Maastricht study. J Hypertens. 2015; 33: 1651-1657. Ref.: https://goo.gl/MNjpzJ
Berezin AE, Kremzer AA. Analysis of Various Subsets of Circulating Mononuclear Cells in Asymptomatic Coronary Artery Disease. J. Clin Med. 2013; 2: 32-4. Ref.: https://goo.gl/VW6Bhs
Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013; 113: 1-11. Ref.: https://goo.gl/X3aMvt
Berezin AE. Microparticles in Chronic Heart Failure. Advances in Clinical Chemistry/1st Edition. 2017; 1-41. Ref.: https://goo.gl/3A83kG
Berezin AE, Kremzer AA, Berezina TA, Martovitskaya YuV. The pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis. Acta Clin Belg. 2016; 71: 38-45. Ref.: https://goo.gl/ykotCo
Berezin AE. Biomarkers for cardiovascular risk in diabetic patients. Heart. 2016; 102: 1939-1941
Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA. Serum Uric Acid Predicts Declining of Circulating Proangiogenic Mononuclear Progenitor Cells in Chronic Heart Failure Patients. J Cardiovasc Thorac Res. 2014; 6: 153-162. Ref.: https://goo.gl/obBYhU